拉斯米迪坦改善皮质-海马体病理,并改善老年帕金森症小鼠的认知能力
Atsushi Ishii1, Jasmine R Meredith2, Mandi J Corenblum1
1Department of Neurology, College of Medicine, University of Arizona, Tucson, AZ, United States of America.
Experimental neurology
|October 14, 2025
概括
拉斯米迪坦是一种5-HT1F受体激动剂,改善了帕金森氏症患者的认知缺陷和焦虑.
科学领域:
- 神经科学是一个神经科学.
- 线粒体生物学 线粒体生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 线粒体功能障碍是帕金森病 (PD) 发病的核心原因.
- 血清的5-HT1F受体调节了线粒体生物发生 (MB).
研究的目的:
- 评估拉斯米迪坦的治疗潜力,一个5-HT1F受体激动剂,在PD的小鼠模型中.
- 研究拉斯米迪坦对认知和运动功能的影响,线粒体健康和α-synuclein聚合.
主要方法:
- 拉斯米迪坦给Thy1-aSyn"线61"小鼠 (年轻和老) 的使用.
- 评估行为变化 (认知,焦虑,运动).
- 分析线粒体生物发生,线粒体功能和大脑区域的α-synuclein聚合.
主要成果:
- 系统性拉斯米迪坦穿透了大脑,并在年轻的PD小鼠中逆转了认知缺陷和焦虑.
- 拉斯米迪坦增强了线粒体生物发生和功能,减少了皮质-海马体区域的α-synuclein聚合.
- 在接受每日拉斯米迪坦治疗的老年小鼠中,观察到MB和认知能力的轻微改善.
结论:
- 重用拉斯米迪坦可能提供一种策略,以减轻帕金森病的认知衰退.
- 准5-HT1F受体和线粒体生物生成为PD提供了潜在的治疗途径.
相关概念视频
Parkinson's Disease: Treatment
983
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
983
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
558
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
558


